Finnrick, an independent testing programme, publishes 8 assays for Bopeptide Biotechnology: 6 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 2 did not. Most recent assay 8 May 2026.
Bopeptide Biotechnology operates from China, listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/bopeptide-biotechnology.
Bopeptide Biotechnology is listed as active.
No independent third-party assay is on file for Bopeptide Biotechnology, and we have not yet compiled a profile of its own website. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 4 | 3 passed, 1 failed |
| Tirzepatide | 4 | 3 passed, 1 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
Bopeptide Biotechnology is listed as active and we hold 8 Finnrick assays (6 passing, 2 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 8 assays for Bopeptide Biotechnology: 6 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 2 did not. Most recent assay 8 May 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Bpc157 Peptide Review, BPX Research Peptides Review, BraveRX Peptides Review.